Virological rebound and low drug levels of unknown origin under long-acting Cabotegravir (CAB)/Rilpivirine (RPV)

被引：0
|
作者：
Ruff, F. [1 ]
Kalubi, M. [1 ]
Hampel, B. [1 ,2 ]
机构：
[1] Checkpoint Zurich, Zurich, Switzerland
[2] Univ Zurich, Epidemiol Biostat & Prevent Inst, Dept Publ & Global Hlth, Zurich, Switzerland
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：783 / 784
页数：2
相关论文
共 41 条
  • [31] Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
    Oka, Shinichi
    Holohan, Vicki
    Shirasaka, Takuma
    Choi, Jun Yong
    Kim, Yeon-Sook
    Chamay, Nadine
    Patel, Parul
    Polli, Joseph W.
    Ford, Susan L.
    Crauwels, Herta
    Garside, Louise
    D'Amico, Ronald
    Latham, Christine
    van Solingen-Ristea, Rodica
    Baugh, Bryan
    van Wyk, Jean
    [J]. HIV MEDICINE, 2024, 25 (03) : 381 - 390
  • [32] Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study
    Masia, Mar
    Fernandez-Gonzalez, Marta
    Agullo, Vanesa
    Mascarell, Paula
    Padilla, Sergio
    Garcia-Abellan, Javier
    Gutierrez, Felix
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E748 - E751
  • [33] Drug-related neuropsychiatric adverse events across phase III/IIIb studies of long-acting cabotegravir plus rilpivirine through week 48
    Elliot, E.
    Teichner, P.
    Dakhia, S.
    Polli, J.
    Patel, P.
    Garside, L.
    Byrapuneni, S.
    Thiagarajah, S.
    D'Amico, R.
    Van Solingen-Ristea, R.
    Birmingham, E.
    Baugh, B.
    van Wyk, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 157 - 158
  • [34] Expanded multivariable models to assist patient selection for long-acting cabotegravir plus rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virological failure over 152 weeks
    Orkin, C.
    Schapiro, J.
    Perno, C.
    Kuritzkes, D.
    Patel, P.
    DeMoor, R.
    Dorey, D.
    Wang, Y.
    Han, K.
    Van Eygen, V.
    Crauwels, H.
    Ford, S.
    Latham, C.
    St Clair, M.
    Polli, J.
    Vanveggel, S.
    Vandermuelen, K.
    D'Amico, R.
    Garges, H.
    Zolopa, A.
    Spreen, W.
    van Wyk, J.
    Cutrell, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 21 - 22
  • [35] Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice
    Melody, Kevin
    Roy, Chandra N.
    Kline, Christopher
    Cottrell, Mackenzie L.
    Evans, Dwayne
    Shutt, Kathleen
    Pennings, Pleuni S.
    Keele, Brandon F.
    Bility, Moses
    Kashuba, Angela D. M.
    Ambrose, Zandrea
    [J]. JOURNAL OF VIROLOGY, 2020, 94 (08)
  • [36] A combination of viral and participant factors influence virological outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M Phase 3 studies
    Patel, Parul
    Schapiro, Jonathan
    Perno, Carlo
    Kuritzkes, Daniel
    Cutrell, Amy
    Dorey, David
    Wang, Yongwei
    Van Eygen, Veerle
    Crauwels, Herta
    Ford, Susan
    Talarico, Christine
    St Clair, Marty
    Jeffrey, Jerry
    Vandermeulen, Kati
    Spreen, William
    Van Lunzen, Jan
    [J]. HIV MEDICINE, 2021, 22 : 26 - 27
  • [37] Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir plus Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure
    Orkin, Chloe
    Schapiro, Jonathan M.
    Perno, Carlo F.
    Kuritzkes, Daniel R.
    Patel, Parul
    DeMoor, Rebecca
    Dorey, David
    Wang, Yongwei
    Han, Kelong
    Van Eygen, Veerle
    Crauwels, Herta
    Ford, Susan L.
    Latham, Christine L.
    St. Clair, Marty
    Polli, Joseph W.
    Vanveggel, Simon
    Vandermeulen, Kati
    D'Amico, Ronald
    Garges, Harmony P.
    Zolopa, Andrew
    Spreen, William R.
    van Wyk, Jean
    Cutrell, Amy G.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) : 1423 - 1431
  • [38] Safety, efficacy and durability of long-acting CAB and RPV as two-drug IM maintenance therapy for HIV-1 infection: LATTE-2 Week 160 results
    Margolis, D.
    Gonzalez Garcia, J.
    Stellbrink, H.
    Yazdanpanah, Y.
    Richmond, G.
    Smith, G.
    Sutton, K.
    Dorey, D.
    Zhang, F.
    Smith, K.
    Williams, P.
    Spreen, W.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [39] Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance
    Gerstenberg, Jacob
    Klinker, Hartwig
    Baier, Michael
    von Braun, Amrei
    Seybold, Ulrich
    Helbig, Carlotta
    Daeumer, Martin
    Korn, Klaus
    Stephan, Christoph
    Schleenvoigt, Benjamin T.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [40] Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase
    Melody, Kevin
    McBeth, Sarah
    Kline, Christopher
    Kashuba, Angela D. M.
    Mellors, John W.
    Ambrose, Zandrea
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) : 7762 - 7770
12345